MaxCyte to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
Month: November 2022
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Study Conducted by Dr. Vince Clinical ResearchKANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...
NRC Health Study Finds Trust in Local Hospitals and Health Systems Increased During the Pandemic
Trust in individual healthcare providers depends largely on patients’ language preferences U.S. counties where provider trust is highest and lowest...
Vaxxinity to Present at Upcoming Investor Conferences in November
DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
Aleafia Health Expands Sunday Market House of Brands With Coveted Lineup of Winter Product Launches
16 total new listings added to the Sunday Market portfolio by February 20239 new Divvy products in profitable flower, vape,...
Pardes Biosciences to Present at Jefferies London Healthcare Conference
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the...
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late...
T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule
LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection...
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage,...
QHSLab, Inc. Meets the Demand for Updated Mental Health Screening Recommendations from the U.S. Preventive Services Task Force
The latest recommendations from the U.S. Preventive Services Task Force (USPSTF) indicate that all adults under the age of 65...
SciSparc: Wellution™ Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms
Agreement is expected to optimize handling and shipment processes and reduce direct sales costs TEL AVIV, Israel, Nov. 01, 2022...
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Activated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in...
Dentsply Sirona Completes Internal Investigation
Announces Restatements of Third Quarter 2021 and Full Year 2021 Financials Reports Select Preliminary Third Quarter 2022 Results CHARLOTTE, N.C.,...
CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing...
Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
Cingal 19-01: Significant Reduction in WOMAC Pain from Baseline 19-01: Change in WOMAC Pain from Baseline (ITT)Study Demonstrated Superiority of...
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty...
Candel Therapeutics Upcoming Investor Conference Participation for November
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel...